Peijia Medical Limited Cash Flow Conversion Efficiency
Peijia Medical Limited cash flow conversion efficiency. Based on the latest financial reports, Peijia Medical Limited (4WO) has a cash flow conversion efficiency ratio of -0.096x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-235.16 Million ≈ $-274.93 Million USD) by net assets (€2.44 Billion ≈ $2.86 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Peijia Medical Limited (2018–2025)
Cash flow conversion efficiency of Peijia Medical Limited from 2018 to 2025. This chart illustrates how Peijia Medical Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Peijia Medical Limited share price for real-time trading data and today's change.
Peijia Medical Limited Cash Flow Conversion Ratio Explained
Peijia Medical Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Peijia Medical Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Peijia Medical Limited ranked by their cash flow conversion efficiency. Also see 4WO market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Xinning Modern Logist
SHE:300013
|
0.215x |
|
Trifork Holding AG
CO:TRIFOR
|
0.035x |
|
Chien Kuo Construction Co Ltd
TW:5515
|
0.029x |
|
Hyliion Holdings Corp.
NYSE:HYLN
|
-0.052x |
|
Shandong Sito Bio-technology Co Ltd
SHE:300583
|
0.008x |
|
Canopy Growth Corp
NASDAQ:CGC
|
-0.036x |
|
Microtek International Inc
TW:2305
|
0.027x |
|
Fujian Superpipe
SHE:300198
|
0.019x |
Annual Cash Flow Conversion Efficiency for Peijia Medical Limited (2018–2025)
The table below shows the annual cash flow conversion efficiency of Peijia Medical Limited from 2018 to 2025. Review 4WO financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.86 Billion ≈ $2.17 Billion |
€-20.89 Million ≈ $-24.42 Million |
-0.011x | -343.81% |
| 2024-12-31 | €2.04 Billion ≈ $2.39 Billion |
€-5.18 Million ≈ $-6.06 Million |
-0.003x | +99.09% |
| 2023-12-31 | €2.27 Billion ≈ $2.66 Billion |
€-630.91 Million ≈ $-737.60 Million |
-0.277x | -94.52% |
| 2022-12-31 | €2.64 Billion ≈ $3.08 Billion |
€-376.20 Million ≈ $-439.81 Million |
-0.143x | +1.32% |
| 2021-12-31 | €3.02 Billion ≈ $3.53 Billion |
€-436.37 Million ≈ $-510.16 Million |
-0.145x | -124.52% |
| 2020-12-31 | €2.81 Billion ≈ $3.29 Billion |
€-181.10 Million ≈ $-211.72 Million |
-0.064x | -135.03% |
| 2019-12-31 | €-558.21 Million ≈ $-652.60 Million |
€-102.59 Million ≈ $-119.94 Million |
0.184x | -55.23% |
| 2018-12-31 | €-94.34 Million ≈ $-110.29 Million |
€-38.73 Million ≈ $-45.28 Million |
0.411x | -- |
About Peijia Medical Limited
Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People's Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company's products inc… Read more